Pharmanovia In-Licenses Catumaxomab from Lindis Biotech for Malignant Ascites

Pharmanovia, a global pharmaceutical company focused on commercializing innovative medicines and revitalizing established ones, today announced the expansion of its oncology portfolio with a new licensing agreement for catumaxomab. This agreement will enable the treatment of malignant ascites, a rare…

Read MorePharmanovia In-Licenses Catumaxomab from Lindis Biotech for Malignant Ascites

Study in Heart Rhythm Shows AI Algorithms Cut Alert Burden with PaceMate’s Data Capabilities

A recent study published in Heart Rhythm highlights how artificial intelligence (AI) algorithms embedded in Medtronic’s LINQ II implantable loop recorders (ILRs) significantly reduce alert and episode burdens. This is achieved through data analysis powered by PaceMate’s flagship product, PaceMateLIVE™.…

Read MoreStudy in Heart Rhythm Shows AI Algorithms Cut Alert Burden with PaceMate’s Data Capabilities

Peek Launches First-Ever ‘Prescription Marketplace’ to Revolutionize Employer Benefits

While every company wants to support their employees’ health, businesses of all sizes face challenges with rising healthcare costs and complex, confusing benefit plans. Prescription medications can be a tough challenge for many people. Faced with the decision of whether…

Read MorePeek Launches First-Ever ‘Prescription Marketplace’ to Revolutionize Employer Benefits

Sangamo Therapeutics Gets FDA IND Clearance for ST-503 in Treating Idiopathic Small Fiber Neuropathy

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a leader in genomic medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application for its ST-503 program. ST-503 is an experimental epigenetic regulator being developed…

Read MoreSangamo Therapeutics Gets FDA IND Clearance for ST-503 in Treating Idiopathic Small Fiber Neuropathy

Rocket Pharmaceuticals Publishes Phase 1 RP-A501 Data in NEJM, Presents at AHA Conference 2024

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading biotechnology company focused on developing genetic therapies for rare, life-threatening diseases, announced promising long-term safety and efficacy data from its Phase 1 RP-A501 study. The results were presented at the 2024 American Heart…

Read MoreRocket Pharmaceuticals Publishes Phase 1 RP-A501 Data in NEJM, Presents at AHA Conference 2024

Encora Therapeutics Completes ULTRE Trial for Wrist-Worn Essential Tremor Device

Encora Therapeutics is excited to announce the successful completion of the ULTRE (Upper Limb Tremor Reduction in Essential Tremor) clinical trial. The study assessed the safety, tolerability, and effectiveness of Encora’s innovative wrist-worn stimulation device for individuals with essential tremor…

Read MoreEncora Therapeutics Completes ULTRE Trial for Wrist-Worn Essential Tremor Device

Vir Biotechnology Announces Positive Chronic Hepatitis Delta Trial Data and Phase 3 Program Launch

Vir Biotechnology, Inc. (NASDAQ:VIR) today revealed positive results from the SOLSTICE Phase 2 clinical trial evaluating its investigational combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD). The trial, which included both monotherapy and combination therapy…

Read MoreVir Biotechnology Announces Positive Chronic Hepatitis Delta Trial Data and Phase 3 Program Launch

Lobe Sciences and Alera Pharma Announce Second U.S. Patent Allowance for Conjugated Psilocin™

Lobe Sciences, Ltd. (CSE: LOBE, OTCQB: LOBEF) and Alera Pharma, Inc. today announced the receipt of a second patent allowance for their Conjugated Psilocin™ technology. The patent, titled “Stable Psilocin Salts, Esters, and Conjugates and Uses Thereof,” covers compositions that…

Read MoreLobe Sciences and Alera Pharma Announce Second U.S. Patent Allowance for Conjugated Psilocin™

Supercomputing 2024: ALAFIA Unveils Personal Supercomputers for Precision Medicine & AI

Alafia AI, Inc. (“ALAFIA”), a leader in omics computing and precision medicine, is today unveiling an expansion of its high-performance computing (HPC) product line to address the growing demand for scalable, heterogeneous computing in the biopharmaceutical and application development industries.…

Read MoreSupercomputing 2024: ALAFIA Unveils Personal Supercomputers for Precision Medicine & AI